Sonoma Pharmaceuticals (SNOA) Current Assets (2011 - 2026)

Sonoma Pharmaceuticals' Current Assets history runs 16 years deep, the most recent figure standing at $12.1 million for Q1 2026.

• On a quarterly basis, Current Assets fell 4.33% year-over-year to $12.1 million in Q1 2026; TTM through Mar 2026 was $12.1 million, a 4.33% decrease from a year earlier, with the FY2026 full-year figure at $12.1 million, down 4.33% from the prior year.
• Current Assets held at $12.1 million in Q1 2026 per SNOA's latest filing, from $12.1 million in the prior quarter.
• Across five years, Current Assets topped out at $16.4 million in Q1 2022 and bottomed at $11.2 million in Q4 2022.
• The 5-year median for Current Assets is $12.5 million (2025), against an average of $12.8 million.
• Biggest YoY gain for Current Assets was 26.55% in 2022; the steepest drop was 36.54% in 2022.
• Year by year, Current Assets stood at $11.2 million in 2022, then grew by 11.31% to $12.5 million in 2023, then decreased by 0.98% to $12.4 million in 2024, then retreated by 1.9% to $12.1 million in 2025, then slipped by 0.37% to $12.1 million in 2026.
• Per Business Quant, the three latest SNOA Current Assets figures stand at $12.1 million (Q1 2026), $12.1 million (Q4 2025), and $12.5 million (Q3 2025).